Raymond James Increases Solazyme Price Target to $12.50 (SZYM)

Share on StockTwits

Solazyme (NASDAQ: SZYM) had its price target increased by Raymond James from $10.50 to $12.50 in a research report sent to investors on Monday morning, Stock Ratings Network.com reports. The firm currently has an outperform rating on the stock.

A number of other analysts have also recently weighed in on SZYM. Analysts at Robert W. Baird raised their price target on shares of Solazyme from $10.00 to $12.00 in a research note to investors on Friday, May 10th. They now have an outperform rating on the stock. Analysts at Morgan Stanley initiated coverage on shares of Solazyme in a research note to investors on Friday, April 19th. They set an overweight rating on the stock.

Nine equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of Buy and an average price target of $12.63.

Shares of Solazyme (NASDAQ: SZYM) opened at 11.91 on Monday. Solazyme has a 52 week low of $6.45 and a 52 week high of $14.34. The stock’s 50-day moving average is currently $8.1. The company’s market cap is $736.4 million.

Solazyme, Inc. (NASDAQ: SZYM) makes oil.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Latest News

Windows 10 Scam Being Sent Via Email
Windows 10 Scam Being Sent Via Email
FireEye Shares Drop Prior to Opening Bell on CFO Departure
FireEye Shares Drop Prior to Opening Bell on CFO Departure
Goodyear Profit Exceeds Estimates on Demand in North America
Goodyear Profit Exceeds Estimates on Demand in North America
Allergen Bid Might Be Better for Teva
Allergen Bid Might Be Better for Teva
Biogen Slashes Forecast on Weakness of Tecfidera
Biogen Slashes Forecast on Weakness of Tecfidera
Whirlpool Profit for the Quarter Drops on Strong Dollar
Whirlpool Profit for the Quarter Drops on Strong Dollar


Advertisement
Advertisement
© 2006-2015 Ticker Report. Google+.